ERBB2 and breast cancer: Here we demonstrate not only the feasibility of establishing unique HER2+ and triple-negative immortalized primary breast cancer cell lines from their respective PDX tumors, but also draw genetic and drug phenotype comparisons between their respective organoid, PDX, and original patient primary tumor.